NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Petco Health and Wellness Company, Inc. (“Petco” or the “Company”) (NASDAQ: WOOF).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Petco and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class act ...

BENSALEM, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NEOGEN CORPORATION (NEOG), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by ...

SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving EchoStar Corporation (NASDAQ: SATS) focused on whether EchoStar and certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the EchoStar investigation or if you are an EchoStar investor who suffered a loss and would like t ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Rocket Pharmaceuticals and its officers or directors following a serious adverse event in a clinical trial that led to a significant drop in the company's stock price [1][3]. Group 1: Company Developments - On May 27, 2025, Rocket Pharmaceuticals announced an unexpected serious adverse event (SAE) related to its investigational gene therapy RP-A501 for Danon disease, which involved clinical complications from capillary leak syndrome [3]. - Following the SAE, Rocket voluntarily paused further dosing in the Phase 2 pivotal trial, and the FDA placed a clinical hold on the trial for further evaluation [3]. - The patient involved in the SAE subsequently passed away due to an acute systemic infection [3]. Group 2: Market Reaction - The announcement of the SAE resulted in Rocket's stock price falling by $3.94 per share, a decrease of 62.84%, closing at $2.33 per share on May 27, 2025 [3]. Group 3: Legal Context - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is representing investors in the investigation regarding Rocket Pharmaceuticals [1][4].

BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Savara Inc. (Nasdaq: SVRA) for potential securities law violations. Investors who have lost money in their Savara Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/svra. What is this all about? Shares of Savara fell over 30% in intraday trading on May 27, 2025, after the company announced that the FDA issued a Refusal to File letter f ...

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Methanex Corporation and its officers or directors [1]. Group 1: Company Performance and Events - On March 9, 2025, Methanex announced an unplanned outage at its 1.8 million tonne methanol plant, Geismar 3, in Louisiana, which occurred in late February [3]. - Following the outage announcement, Methanex's management decided to repair the autothermal reformer (ATR) and estimated a plant startup by early May 2025 [3]. - The stock price of Methanex fell by $5.45 per share, or 12.9%, closing at $36.80 per share on March 10, 2025, after the announcement [4]. Group 2: Legal and Regulatory Context - Pomerantz LLP, a firm known for its work in corporate, securities, and antitrust class litigation, is leading the investigation into Methanex [5]. - The firm has a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5].